Beam Therapeutics Stock News

Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.

These stocks are poised for a strong year.

These stocks are poised for a strong year.

First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that J

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh

Beam Therapeutics Inc. (NASDAQ:BEAM) insider Giuseppe Ciaramella sold 25,104 shares of Beam Therapeutics stock in a transaction on Tuesday, December 21st. The stock was sold at an average price of $85.69, for a total transaction of $2,151,161.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Shares []

Analysts predict that Beam Therapeutics Inc. (NASDAQ:BEAM) will post $4.00 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Beam Therapeutics earnings, with estimates ranging from $500,000.00 to $7.50 million. Beam Therapeutics posted sales of $10,000.00 in the same quarter last year, which suggests a positive year-over-year growth []

Equities research analysts predict that Beam Therapeutics Inc. (NASDAQ:BEAM) will post earnings of ($0.94) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Beam Therapeutics earnings. The lowest EPS estimate is ($1.15) and the highest is ($0.35). Beam Therapeutics reported earnings of ($0.72) per share in the same quarter last []

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Beam (CURRENCY:BEAM) traded up 0.3% against the dollar during the 24 hour period ending at 13:00 PM E.T. on December 21st. Beam has a total market capitalization of $61.34 million and approximately $6.54 million worth of Beam was traded on exchanges in the last 24 hours. In the last week, Beam has traded 6.3% higher []

BEAM's novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations. While the 'standard' CRISPR-cas9 approach cuts double-stra

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

DekaBank Deutsche Girozentrale raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM) by 188.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,300 shares of the companys stock after purchasing an additional 10,000 shares during the quarter. DekaBank Deutsche Girozentrales holdings []